Ketamine Research: Studies and Evidence
A plain-language guide to the studies that shaped modern ketamine research, where the evidence is strongest, and where it is still developing.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
- The strongest evidence is for treatment-resistant depression, backed by multiple RCTs and FDA approval of esketamine (Spravato).
- Effect sizes are meaningful but heterogeneous; not everyone responds, and durability without maintenance is limited.
- Suicidal ideation reductions are among the most consistently replicated short-term findings.
- Evidence in PTSD, anxiety, OCD, and chronic pain is promising but earlier-stage and less definitive.
- Long-term safety data (multi-year, real-world) is still accumulating — clinical practice runs ahead of the trial literature.
Landmark studies (summarized)
- Berman et al., 2000 - first small placebo-controlled trial showing rapid antidepressant effects.
- Zarate et al., 2006 - replicated rapid effects in treatment-resistant depression.
- Murrough et al., 2013 - larger randomized trial confirming rapid response.
- Daly et al., 2018 & 2019 - esketamine pivotal trials supporting FDA approval.
- Feder et al., 2014 & 2021 - evidence for ketamine in PTSD with repeated dosing.
Timeline of the field
- 1960s: Ketamine developed and approved as an anesthetic.
- 1990s–2000s: Researchers observe rapid antidepressant effects at subanesthetic doses.
- 2010s: Repeated-dose protocols, mechanism studies, and trials in PTSD expand.
- 2019: FDA approves esketamine (Spravato) for treatment-resistant depression.
- 2020s: Growing focus on durability, integration with therapy, and long-term safety.
How to read clinical evidence
- Trial design matters: Randomized, placebo-controlled trials carry more weight than open-label studies.
- Effect size and duration: Statistical significance is not the same as clinical durability.
- Generalizability: Trial participants may differ from people seen in community clinics.
- Conflicts of interest: Industry-funded trials are not invalid, but disclosure context matters.
Reputable starting points
Where evidence is still developing
Long-term safety, optimal dosing schedules, durability of response, use in adolescents and older adults, and the role of integration therapy all remain active research areas. Responsible reading acknowledges these gaps rather than minimizing them.
See also: Research & neuroscience, How ketamine works, and safety & eligibility.
Frequently asked questions
Is ketamine FDA-approved for depression?+
Esketamine (Spravato), a nasal-spray form, is FDA-approved for treatment-resistant depression within a restricted program. Generic IV/IM ketamine for depression is typically administered off-label.
What does the strongest evidence support?+
The most robust evidence supports rapid, often short-lived antidepressant effects of subanesthetic ketamine and intranasal esketamine in adults with treatment-resistant depression.
How long do benefits last?+
Single-dose benefits commonly fade within days to a couple of weeks. Repeated dosing and integrated care are typically needed for durability.
Is there evidence for PTSD, anxiety, and OCD?+
There is a smaller, developing evidence base for PTSD and certain anxiety presentations. Evidence for OCD is more limited and mixed.
Where can I find primary sources?+
Reputable starting points include the NIH/NIMH, PubMed, ClinicalTrials.gov, and peer-reviewed journals such as JAMA Psychiatry and The American Journal of Psychiatry.
References
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.